SPINCOMS Biomarker Study

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2020
To determine if biomarker-based CSF testing is reliably detecting differences between patients with Multiple Sclerosis (MS), different MS-subtypes, and other central nervous system (CNS) diseases. This study will also look to identify biomarkers that could be used for the prediction, at the time of diagnosis, of the future disease clinical course and response to therapy. The SOMAscan assay will be used for CSF samples analysis.
Epistemonikos ID: 7df0fbb2e641361df690d81b8fb99705ba4f95d7
First added on: May 07, 2024